

**Priority question for written answer P-001596/2025
to the Commission**
Rule 144
Tomislav Sokol (PPE)

Subject: EU dependency on US pharmaceutical imports and lack of adequate substitutes

There is information indicating that the EU depends on the import of certain pharmaceutical products from the United States for which there are currently no adequate substitutes available within the EU. This dependency appears to be particularly significant in the following areas: advanced biologics and specialty medicines, including monoclonal antibodies and innovative treatments for cancer and autoimmune diseases; active pharmaceutical ingredients used in essential medicines where EU-based production is limited or unavailable; and innovative therapies and orphan drugs, often developed and produced primarily in the United States. These dependencies raise concerns regarding the EU's strategic autonomy and the resilience of its pharmaceutical supply chains. In the light of the above:

1. Can the Commission confirm whether there are pharmaceutical products currently imported from the United States which have no adequate substitute within the EU?
2. What exactly are these products, and does the Commission maintain a classification or list of such pharmaceutical dependencies?
3. What measures is the Commission taking both to reduce the EU's dependency on imports of these medicines and to support domestic production in strategically important pharmaceutical sectors?

Submitted: 22.4.2025